RARE•businesswire•
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit
Summary
SAN DIEGO--(BUSINESS WIRE)---- $RARE #Health--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025. Ultragenyx is a biopharmaceutical company focused on rare and ultrarare genetic disorders. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigat
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 5, 2026 by businesswire